Canadian Centre on Substance Use and Addiction Looks Forward to Federal Cannabis Act Review
OTTAWA – The Canadian Centre on Substance Use and Addiction (CCSA) welcomes the planned federal cannabis review and looks forward to opportunities to contribute evidence on public health, public safety and equity. This evidence is based on research by our experts and with communities in keeping with CCSA’s legislated role to provide neutral, data-driven, third-party advice to help governments, organizations and individuals make informed decisions on issues of substance use and addiction.
“We feel the review provides an important opportunity to ensure Canada is achieving the public health and safety objectives it set when legalizing cannabis. It will also help the public understand what has been learned and researched,” says CEO Dr. Alexander Caudarella.
On-Premise Cannabis Use: Public Health and Safety Considerations and Cannabis Legalization: 2021-2022 Observations are the latest in CCSA’s suite of cannabis resources. Others include a Is It OK to Use Cannabis Use During Pregnancy and Breastfeeding public awareness poster and a Knowing Your Limits with Cannabis: A Practical Guide to Assessing Cannabis Use booklet, both of which focus on harm reduction techniques.
(This information is primarily sourced from Canadian Centre on Substance Use and Addiction. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
California Cannabis Brand, Rose, Teams Up with Kiva Sales and Service to Expand Product Line
LOS ANGELES-- Rose, California's cannabis brand, announced today an exclusive partnership with Kiva Sales and Service (KSS), a top sales and distribution platform that offers dispensaries a curated selection of the best brands in the ...
Australian Nurses Call for Medicinal Cannabis Education in Undergraduate Degrees
The group wants education about the endocannabinoid system included in undergraduate nursing degrees. Seven years ago, the Federal Parliament passed legislation to legalise medicinal cannabis in Australia. Since then, most cannabis medications have been classified ...
Psychedelic Firm Reunion Neuroscience Sues Mindset Pharma for Patent Infringement and Breach of Contract
LOS ANGELES-- Clinical research firm Reunion Neuroscience Inc. has filed a lawsuit against Mindset Pharma Inc. in federal court, alleging that the latter copied its psychedelic formula and presented it as its own invention while ...